130 related articles for article (PubMed ID: 31204194)
1. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
[TBL] [Abstract][Full Text] [Related]
2. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.
Mamlouk O; Selamet U; Machado S; Abdelrahim M; Glass WF; Tchakarov A; Gaber L; Lahoti A; Workeneh B; Chen S; Lin J; Abdel-Wahab N; Tayar J; Lu H; Suarez-Almazor M; Tannir N; Yee C; Diab A; Abudayyeh A
J Immunother Cancer; 2019 Jan; 7(1):2. PubMed ID: 30612580
[TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
[TBL] [Abstract][Full Text] [Related]
4. Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.
Leitinger M; Varosanec MV; Pikija S; Wass RE; Bandke D; Weis S; Studnicka M; Grinzinger S; McCoy MR; Hauer L; Sellner J
Front Immunol; 2018; 9():108. PubMed ID: 29441072
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease.
Kitchlu A; Jhaveri KD; Wadhwani S; Deshpande P; Harel Z; Kishibe T; Henriksen K; Wanchoo R
Kidney Int Rep; 2021 Jan; 6(1):66-77. PubMed ID: 33426386
[TBL] [Abstract][Full Text] [Related]
6. Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis.
Powers CM; Yang AK; Verma H; Orloff J; Piontkowski AJ; Gulati N
JMIR Dermatol; 2024 May; 7():e53792. PubMed ID: 38696235
[No Abstract] [Full Text] [Related]
7. Narrative Review of Hypercoagulability in Small-Vessel Vasculitis.
Claudel SE; Tucker BM; Kleven DT; Pirkle JL; Murea M
Kidney Int Rep; 2020 May; 5(5):586-599. PubMed ID: 32405580
[TBL] [Abstract][Full Text] [Related]
8. Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report.
Duarte R; Trigo F; Luz I; Santos P
Melanoma Res; 2024 Feb; 34(1):76-79. PubMed ID: 38016155
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab.
Lin JS; Wang DY; Mamlouk O; Glass WF; Abdelrahim M; Yee C; Abudayyeh A
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020246
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor therapy associated with IgA nephropathy: a case report and literature review.
Chabannes M; Lisri Z; Lang S; Seibel J; Eberst G; Ducloux D; Pursun C; Durey MAD; Alyanakia MA; Felix S; Crepin T
Front Immunol; 2024; 15():1393901. PubMed ID: 38807591
[TBL] [Abstract][Full Text] [Related]
11. Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.
Piscitani L; Sirolli V; Di Liberato L; Morroni M; Bonomini M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664269
[TBL] [Abstract][Full Text] [Related]
12. T-cell prolymphocytic leukaemia associated with immune checkpoint inhibitor (pembrolizumab).
Avelino AR; Elmanaseer O; Wrzesinski S; Raval M
BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35351740
[TBL] [Abstract][Full Text] [Related]
13. Nephrological Detrimental Impacts Resulting From Novel Immunotherapy Drugs Used in the Treatment of Cancer: A Systematic Review.
Jaiswal A; Shergill K; Boppana K; Almansouri NE; Bakkannavar S; Faheem Y; Nath TS
Cureus; 2024 Feb; 16(2):e54487. PubMed ID: 38516472
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management.
Seethapathy H; Herrmann SM; Sise ME
Kidney Med; 2021; 3(6):1074-1081. PubMed ID: 34939017
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced SJS/TEN-like reaction.
Fazelpour S; Gibson F; Caligayahan M; Vashi N
Arch Dermatol Res; 2024 May; 316(6):264. PubMed ID: 38795166
[No Abstract] [Full Text] [Related]
16. Renal mass-forming granulomatous inflammation associated with immune checkpoint inhibitor therapy.
Chua DYS; Ong CSH; Goh BYS; Tan NJH
Pathology; 2024 Apr; 56(3):421-423. PubMed ID: 37716817
[No Abstract] [Full Text] [Related]
17. Late relapse of IgM nephropathy-associated nephrotic syndrome after repeated administration of immune checkpoint inhibitor against pulmonary adenocarcinoma.
Odani K; Tachibana M; Nogaki F; Tsutsumi Y
Clin Case Rep; 2021 Apr; 9(4):1917-1924. PubMed ID: 33936615
[TBL] [Abstract][Full Text] [Related]
18. Low Serum C3 Pauci-Immune Glomerulonephritis: High Histopathological Activity and Lower Rates of Response to Standard Therapies.
Lionaki S; Boletis JN
Kidney Int Rep; 2021 Nov; 6(11):2930. PubMed ID: 34805645
[No Abstract] [Full Text] [Related]
19. Hyperacute Onset of Immune Checkpoint Inhibitor-Related Acute Interstitial Nephritis.
Tawhari I; Fenton SE; Sosman JA; Sustento-Reodica N; Kanwar YS; Aggarwal V
Kidney Int Rep; 2020 Nov; 5(11):2084-2088. PubMed ID: 33163728
[No Abstract] [Full Text] [Related]
20. Immune Checkpoint Inhibitors for Kidney and Bladder Cancer: Adrenotoxic Consequences.
Liblik K; Caterini J; Touma NJ
Urology; 2024 Feb; ():. PubMed ID: 38431157
[No Abstract] [Full Text] [Related]
[Next] [New Search]
